Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18713239 | 0.80 | RET (0.48) | — | |
| SCHEMBL20069809 | 0.79 | ALDH1A1 (0.48) | SIGMAR1ALDH1A1KDM4EMAPTALOX15 | |
| Hydrochloric Acid SCHEMBL31003019 | 0.76 | SIGMAR1 (0.44) | SIGMAR1ALDH1A1KDM4EMAPTALOX15 | |
| SCHEMBL4851071 | 0.73 | LTA4H (0.51) | SIGMAR1ALDH1A1KDM4EMAPTALOX15 | |
| SCHEMBL24135073 | 0.73 | SIGMAR1 (0.50) | SIGMAR1ALDH1A1HPGDKDM4EMAPT | |
| SCHEMBL31003008 | 0.72 | ALDH1A1 (0.48) | ALDH1A1HPGDMAPTLTA4H | |
| SCHEMBL22031239 | 0.72 | RET (0.47) | — | |
| SCHEMBL20328021 | 0.72 | SIGMAR1 (0.68) | SIGMAR1ALDH1A1 | |
| SCHEMBL22812097 | 0.70 | PDE10A (0.33) | — | |
| SCHEMBL13889211 | 0.70 | KDM4E (0.55) | SIGMAR1ALDH1A1KDM4EMAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | SIGMAR1 3863/4885ALDH1A1 2868/4885HPGD 3857/4885 |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | SIGMAR1 3863/4885ALDH1A1 2868/4885HPGD 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.